Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Jun 30, 2009

Life Technologies Sells LIMS Business to LabVantage

  • Life Technologies has divested the SQL*LIMS business to LabVantage Solutions. It is used for tracking raw materials and samples as they enter and travel through the laboratory workflow, sample analysis, data collection, and communication of this information to corporate systems.

    “While the LIMS business is an important asset for a segment of our customers, it was not a perfect fit with our strategic direction,” comments Mark Stevenson, Life Technologies’ president and COO. Life Technologies was formed from the $6.7 billion acquisition of Applied Biosystems and Invitrogen in June 2008. The new firm is focussed on selling instruments, systems, and reagents to drug R&D companies.

    “We are confident that our customers will benefit from the increased focus of a software solutions company,” remarks Pat Pijanowski, GM, SQL*LIMS business unit for Life Technologies.

    The transaction is expected to close in the third quarter. It is not expected to have a material effect on the firm's financials for this year, according to Life Technologies.


Related content

Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »